Key result
Deferred stenting with apixaban improves 6-month TIMI III flow to ~94% over immediate stenting.
Why the study?
In STEMI with high thrombus burden, immediate stenting increases distal embolization and may impair myocardial recovery, while the optimal adjunctive therapy for deferred stenting remains uncertain.
Does deferred stenting with triple therapy including apixaban improve TIMI flow and myocardial blush grade at 6 months compared to immediate stenting or deferred stenting with DAPT in STEMI patients with high thrombus burden?
RCT (n=150)
Three-group randomization
Does deferred stenting with triple therapy including apixaban improve TIMI flow and myocardial blush grade at 6 months compared to immediate stenting or deferred stenting with DAPT in STEMI patients with high thrombus burden?
In STEMI patients with high thrombus burden, deferred stenting combined with triple therapy including apixaban significantly improved 6-month microvascular perfusion (TIMI III flow and MBG 3) and LVEF recovery compared to DAPT or immediate stenting, though short-term MACE and mortality were unchanged.
Answers are grounded in this paper and cite their sources.
Improves microvascular perfusion surrogates in high-thrombus STEMI; extends deferred stenting data but leaves MACE benefit unproven.
Background In STEMI with high thrombus burden, immediate stenting increases distal embolization, potentially impairing myocardial recovery. Deferred stenting might improve outcomes, but the optimal adjunctive therapy remains uncertain. Purpose To evaluate the effects of deferred stenting with dual antiplatelet therapy (DAPT) and triple therapy (including Apixaban) on myocardial recovery and microvascular perfusion in high thrombus burden STEMI. Methods In this randomized trial, 150 STEMI patients with high thrombus burden were assigned to three groups: immediate stenting, deferred stenting with DAPT, or deferred stenting with triple therapy including Apixaban. The primary endpoints were TIMI flow and myocardial blush grade (MBG) at 6 months. Secondary endpoints included major adverse cardiovascular events (MACE), reinfarction, stroke, mortality, and left ventricular ejection fraction (LVEF) assessed by 3D speckle-tracking echocardiography. Results Deferred stenting with Apixaban led to superior angiographic and functional outcomes. TIMI III flow was achieved in 94% of patients in the Apixaban group compared to 76% in the DAPT group (p=0.03). MBG 3 was observed in 82.9% of patients in the Apixaban group, compared to 70.9% in DAPT and 30% in the immediate stenting group (p<0.01). Apixaban significantly reduced no-reflow (p<0.01) and improved LVEF (+14.5% vs. +12.9%, p=0.0067). No significant differences were noted in MACE and mortality at 6 months (p=0.45 and p=0.52, respectively). Conclusion Deferred stenting with triple therapy, including Apixaban, improves myocardial recovery and microvascular perfusion in high thrombus burden STEMI without reducing short-term MACE. Larger studies are needed to assess long-term survival and benefits.
No takes yet. Share an insight, caveat, or question.
Shehata et al. (2026) conducted an RCT in STEMI with high thrombus burden (n=150). Deferred stenting with triple therapy including Apixaban vs. Deferred stenting with DAPT or immediate stenting was evaluated on TIMI flow and myocardial blush grade (MBG) at 6 months (p=0.03). Deferred stenting with Apixaban achieved superior TIMI III flow and MBG 3 at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: